MBX Biosciences, Inc. (MBX) Balance Sheet
As of 2026-06-30 (10-Q), MBX Biosciences, Inc. (MBX) reported total assets of $435.9M, total liabilities of $26.4M and shareholders' equity of $409.5M, according to EquiReason's reading of its SEC filings. Cash and equivalents: $54.1M.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
MBXMBX Biosciences, Inc.Follow MBX — free
—
Price chart with a free account
- Market cap
- 2.3B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 5 Nov, in 12 days
| Line | FY2024 Dec 24 | FY2025 Dec 25 | Latest Jun 26 | Trend |
|---|---|---|---|---|
| Cash and equivalents | 49.4 | 75.3 | 54.1 | |
| Short-term investments | 212.8 | 298.4 | 364.5 | |
| Current assets | 267.3 | 381.5 | 427.9 | |
| Total assets | 268.5 | 385.1 | 435.9 | |
| Current liabilities | 11.1 | 15.5 | 23.7 | |
| Total liabilities | 11.1 | 15.9 | 26.4 | |
| Shareholders' equity | 257.4 | 369.2 | 409.5 |
USD millions · SEC XBRL
MBX Biosciences, Inc. — questions
- How much cash does MBX Biosciences, Inc. have?
- $54.1M in cash and cash equivalents as of 2026-06-30.
- What are MBX Biosciences, Inc.'s total assets?
- $435.9M as of 2026-06-30.
- What is MBX Biosciences, Inc.'s shareholders' equity?
- $409.5M as of 2026-06-30.
Every figure on this page comes from MBX Biosciences, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.